

A transitional half-year marked by the ongoing sale of Myrian and Intrasense's strategic repositioning toward its DUOnco™ artificial intelligence solutions dedicated to oncology

Montpellier, France, July 23rd, 2026, 05:45 PM. **Intrasense (FR001179886 – ALINS)**, a French expert in AI-enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, releases its half-year revenue figures for the 2026 fiscal year.

In the first half of fiscal year 2026, Intrasense reported a 59.3% decline in consolidated revenue to €646,000 compared with the first half of 2025. This decline is mainly due to scheduling delays affecting the renewal of several maintenance contracts, as well as the receipt of license orders.

All of this revenue was generated within the Myrian business unit, which is currently the subject of an offer from EDL, as announced on July 1, 2026¹.

The completion of the proposed disposal of Myrian® would allow Intrasense to fully focus its resources on the development and commercialization of its DUOnco™ line of artificial intelligence solutions, in collaboration with Guerbet.

A first half of the year marked by new regulatory developments for the DUOnco™ product line

Alongside this transition period, Intrasense continued to execute its strategic roadmap centered on its DUOnco™ artificial intelligence solutions for oncology.

DUOnco™ Pancreas, a solution designed for the early detection of lesions and developed in partnership with Guerbet, has reached another major milestone in its international rollout. After receiving "Breakthrough Device" designation² from the FDA in 2025, the solution obtained regulatory approval in Japan a few weeks ago, opening the way for its commercialization in this strategic market for Intrasense.

At the same time, DUOnco™ Unity is in the final stages of development. It is expected to receive CE marking during the third quarter of 2026. This new solution will round out the DUOnco™ product line by providing a multi-organ AI assistant dedicated to oncology monitoring.

While DUOnco™ Pancreas is designed for the early detection of pancreatic lesions, DUOnco™ Unity will assist radiologists in the longitudinal oncological follow-up of patients through the automated detection, segmentation, and tracking of lesions on CT-TAP scans.

¹ Press release of July 1st, 2026

² Press release of June 8th, 2026

Outlook for the Second Half of 2026: Accelerated Commercial Development of Artificial Intelligence Solutions

In the second half of the year, Intrasense plans in particular to:

- Launch DUOnco™ Unity commercially in Europe at the French Radiology Days (JFR), a major industry event scheduled for October;
- Accelerating the rollout of DUOnco™ Pancreas in Japan through new distribution agreements;
- Continuing installations of DUOnco™ Pancreas and DUOnco™ Unity in France and across Europe, with several contracts already signed or in the process of being completed.

Within this context, Intrasense is entering the second half of the year with a roadmap refocused on artificial intelligence and the goal of accelerating the deployment of its innovative solutions in key international markets. Details of this roadmap will be unveiled during the second half of 2026.

Next financial announcement:

2026 Half-Year Results: September 15 (after market close)

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group since 2023, Intrasense develops medical imaging software solutions that are now firmly focused on artificial intelligence.

Intrasense's product portfolio includes:

- Myrian® (currently being divested), an advanced visualization platform equipped with state-of-the-art clinical tools that simplifies the interpretation of all types of images.
 - DUOnco™: a suite of AI algorithms specialized in oncology, including those for the detection of pancreatic lesions and focal liver lesions, as well as the world's first CE-certified AI dedicated to bone lesions.
- Liflow® (still in the controlled-release phase), a solution designed for the longitudinal monitoring of oncology patients.

By combining clinical expertise and operational excellence, Intrasense provides healthcare professionals with tools of high medical value that facilitate the analysis, diagnosis, and care of patients.

For more information, visit: www.intrasense.fr

Contacts

INTRASENSE

Communication officer

Mathilda Vigne-Salade
Phone: +334 67 13 01 30
investisseurs@intrasense.fr

SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay
Phone: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray
Phone: +33 6 85 36 85 11
isabelle.dray@seitosei-actifin.com